ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2020
[Prognostic Factors of N2 Stage Non-small Cell Lung Cancer after Surgery].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Machine learning models based on XGBoost algorithm to predict prognosis of lung cancer brain metastases.Journal of thoracic disease · 2026Article
- [Review for N2 Sub-staging in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with N2 stage non-small cell lung cancer have prognostic heterogeneity, and this study attempted to explore the prognostic factors among those patients.
methodsPatients with N2 stage undergoing radical resection in Department of Thoracic Surgery, West China hospital, Sichuan University between January 2007 and December 2016 were included. Cox proportional hazard regression model was used to explore the prognostic value of clinicopathological features. Survival curves were plotted by Kaplan-Meier method. Subgroup analyses considering the situation of lymph node involvement were performed.
resultsIn total, 773 patients were included. The median follow-up time was 57.2 months, and the 5-year overall survival rate was 34.8%. Tumor-node-metastasis (TNM) stage, number of involved lymph node stations, skip metastasis, lymphatic or vascular invasion and adjuvant chemotherapy were independent prognostic factors. The patients with stage T1-3 had similar prognosis, while the patients with stage T4 had worse survival. In addition, the patients with single station involvement and skip metastasis had the best prognosis with a 5-years overall survival rate of 48.9%.
conclusionsT4 stage patients had worse survival in N2 group. To get a more precisely stratification, skip metastasis and number of involved lymph node stations should be considered in future N stage classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.